PHP8 A COMPARISON OF POLICIES ON PAEDIATRIC DOSING GUIDELINES AND INDICATIONS BETWEEN THE UNITED STATES AND EUROPE
Nixon F, Chan M, Lock K F F Heron Evidence Development Ltd, Luton, UK OBJECTIVES: To compare legislation on paediatric dosing guidelines and indications between the US and Europe and to examine whether the introduction of new regulations and fi nancial incentives has resulted in more pharmaceutical companies providing paediatric data. METHODS: Information was extracted from published policies and reports on paediatric therapeutics as published by the US Food and Drug Administration and the European Medicines Agency. RESULTS: In the US, the Food and Drug Administration Modernisation Act (FDAMA; 1997) offered six months of marketing exclusivity to manufacturers voluntarily conducting paediatric studies. Current legislation in the US consists of the Best Pharmaceuticals for Children Act (BPCA; 2002) , and the Paediatric Research Equity Act (PREA; 2003) . Manufacturers are also encouraged to obtain orphan drug designation for drugs or biological products for use in a paediatric population. To January 2008, the FDA has sent written requests for paediatric studies to sponsors of 301 drugs. There have been 157 incidents of labeling changes under the BPCA and 76 labeling changes or submissions of supporting information under the PREA. Legislation on paediatric therapeutics was issued in the EU in January 2007 (Regulation (EC) No 1901 No /2006 . Since this time, the EMEA has adopted decisions on 99 applications for paediatric investigational plans (PIPs) and waivers; 57 positive opinions on PIPs; 3 proposed modifi cations to PIPs; and 39 waivers in all age groups for all conditions. Additionally, most European Health Technology Assessment agencies do not make special allowances for the assessment of paediatric therapeutics and dosing. CONCLUSIONS: The introduction of legislation in the US has been successful in encouraging research into the use of therapeutics in paediatric patients. In the EU, although many applications of PIPs and waivers have been reviewed, the situation should be monitored over the coming years to determine if the legislation leads to changes.
PHP9 THE IMPACT OF LEGISLATION AND PRICING ON GENERIC DRUG UTILIZATION: AN ANALYSIS OF 26 COUNTRIES
Patorno E, Margulis A, Cai S, Gagne JJ, Geisler BP, Li Q, Lin SW, Liu W, Palmsten K, Yau WP, Polinski JM Harvard School of Public Health, Boston, MA, USA OBJECTIVES: Across countries with varying political, socioeconomic and cultural environments, we sought to identify predictors of generic drug utilization. METHODS: Data were collected from national and international regulatory agencies, MEDLINE and internet searches for 37 countries classifi ed as "advanced" or "emerging" economies by the International Monetary Fund: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, India, Ireland, Israel, Italy, Japan, Luxembourg, Malta, Mexico, Netherlands, New Zealand, Norway, Portugal, Russia, San Marino, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, UK, United States. We compared the presence of generic policies, fi rst year of generic legislation, branded drug patent duration, proportion of generic drug utilization, and pricing for generics (government control, free market, or other), gross domestic product, and population across countries. Only independent variables with p 0.20 in univariate regression were included in the multivariate model: population, year of generic legislation, patent life, and pricing for generics (market vs. government control). RESULTS: Of 37 countries, data was available for 26 (70%): Argentina, Australia, Austria, Brazil, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Portugal, Russia, Singapore, Spain, Sweden, Switzerland, UK and United States. Most countries enacted generic drug legislation in the 1990s, 9 (35%) introduced legislation before 1990, and 3 (12%) after 2000. Branded drug patent duration was 15-20 years for 65% of countries. Among countries with generic drug laws, only free market-based generic pricing, compared to government-controlled pricing, was associated with a nominal increase in generic drug utilization (B 0.17, 95% CI 0.01, 0.35). CONCLUSIONS: Countries with free market pricing policies had minimally greater diffusion of generic drugs compared to countries with government pricing controls. Further investigation of other characteristics, namely the political and social climates that foster greater generic drug utilization is planned. , and taking medications for any of the following conditions: hypertension, hyperlipidemia, diabetes, asthma/COPD, or depression. RESULTS: In this initial phase, 69 patients were enrolled and 24 (34.8%) reported reaching the coverage gap in 2007. Among in-gap patients, 95% were aged 65-85 years and 58% were female, compared to 73% and 64% respectively for the no-gap subjects. Compared with the no-gap subjects, more in-gap subjects attended college (78% vs. 46%), had a monthly income of $2000 or more (70.8% vs. 56%), and spent more than $300 per month on medications (42% vs. 24%). Compared with no-gap patients, in-gap patients were less likely (54% vs. 69%) to report overall satisfaction with Part-D programs. Finally, 87.5% of the in-gap patients reached the gap in September 2007 or later. CONCLU-SIONS: One-third of the subjects reached the coverage gap and most of them reached the gap within the last quarter of 2007, mitigating the impact of coverage gap to some extent. The in-gap group belonged to higher socioeconomic status, which was expected since the no-gap group appeared not to be at the risk of coverage gap because of low-income subsidies. Experiencing coverage gap negatively impacted patients' satisfaction with Part-D plans.
PHP10 CHARACTERISTICS OF MEDICARE PART-D ENROLLEES WITH AND WITHOUT PRESCRIPTION DRUG COVERAGE GAP

PHP11 THE IMPACT OF NON-REFERRAL OUTPATIENT CO-PAYMENT ON MEDICAL CARE UTILISATION AND EXPENDITURE IN TAIWAN
Chen LC 1 , Schafheutle E 2 , Noyce P 2 , Wen YH 1 , Wu JS 3 1 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2 University of Manchester, Manchester, UK, 3 Bureau of National Health Insurance, Kaohsiung, Taiwan OBJECTIVES: Taiwan's National Health Insurance's (NHI) generous coverage and patients' freedom to access different tiers of medical facilities has resulted in accelerating outpatient care utilisation and cost. To deter non-essential visits and encourage initial contact in primary care, a differential co-payment was introduced on July 15, 2005. Under this, patients pay more for outpatient consultations at higher medical facilities, particularly if accessed without referral. This study aimed to explore the impact of this policy on outpatient medical activities and expenditure, different copayment groups and tiers of medical facilities. METHODS: A segmented time-series analysis on regional weekly outpatient medical claims (January 2004 to July 2006). Outcome variables (number of visits, number of outpatients, total cost of outpatient care) and variables for cost structure were stratifi ed by tiers of medical facilities and co-payment groups. Analysis used the auto-regressive integrated moving-average model in STATA 9.0. RESULTS: The overall number of outpatient visits signifi cantly decreased after policy implementation due to a reduction in the number of patients using outpatient facilities, but total costs of care remained unchanged. The policy had its greatest impact on the number of visits to regional and local community hospitals (secondary), but had no infl uence on those the medical centres (tertiary). Medical utilisation in physician clinics (primary) decreased due to an audit of reimbursement declarations. Overall, the policy failed to encourage referrals from primary care to higher tiers. CONCLUSIONS: Further research needs to explore how patients' outof-pocket payment affects medical utilisation and which forces (not susceptible to copayment) act in tertiary facilities. It also needs to investigate, whether the reduction in outpatient numbers was due to an affordability barrier to accessing essential care, with a potentially negative impact on the region's health.
PHP12 HOW NON-REFERRAL OUTPATIENT CO-PAYMENT IN TAIWAN IMPACTS ON PATIENTS' OUT-OF-POCKET COSTS AND PRESCRIPTION PATTERNS
Chen LC 1 , Schafheutle E 2 , Noyce P 2 , Wen YH 1 , Wu JS 3 1 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2 University of Manchester, Manchester, UK, 3 Bureau of National Health Insurance, Kaohsiung, Taiwan OBJECTIVES: To deter non-essential visits and encourage initial contact in primary care, Taiwan's National Health Insurance's (NHI) implemented a differential copayment policy on July 15, 2005. A previous study has examined the impact of this policy on medical utilization and total cost to NHI using a regional reimbursement dataset. This study aimed to explore the impact of this policy on outpatient copayment and prescription patterns across different co-payment groups and tiers of medical facilities. METHODS: A segmented time-series analysis on regional weekly outpatient medical claims (January 2004 to July 2006). Outcome variables for copayment and prescription patterns were stratifi ed by tiers of medical facilities and copayment groups. Analysis used the auto-regressive integrated moving-average model in STATA 9.0. RESULTS: Despite the decrease in outpatient visits, the overall copayment to patients increased by 1.2% after policy implementation and also increased in most medical facilities (4.8% to 17.9%). Number of general prescriptions decreased across different medical facilities; the average cost and duration per general prescription decreased in medical centers and regional hospitals. The number of continuous prescriptions did not change, except for non-signifi cant decreases in medical centers and regional hospitals. There was an increase in the number of continuous prescriptions dispensed in pharmacies (7.0%). CONCLUSIONS: The police signifi cantly increased patients' out-of-pocket payment for outpatient visits. In response to the policy, physicians might prescribe more expensive drugs and extend prescription duration to help patients get the most benefi t from the co-payment, and physician in medical centers are more likely to prescribe continuous prescriptions for patients with stable chronic diseases. Further research needs to identify vulnerable subgroups in obtaining necessary treatment, and to explore the impacts of cost-saving strategies on patients' quality of medical care.
PHP13 COST-RELATED UNDERUSE OF MEDICINE DUE TO MEDICAID PHARMACY COST-CONTAINMENT POLICY ACTIONS
Kaisaeng N g , Zhang JX Virginia Commonwealth University, Richmond, VA, USA OBJECTIVES: We sought to evaluate the impact of pharmacy cost-containment policy actions by state Medicaid programs on cost-related underuse of medicine, controlling for concurrent non-pharmacy cost-containment policy actions and socio-environmental differences among states. METHODS: We used the data from the 2003 Community Tracking Study (CTS) household survey, and linked them with the census demographic data and the cost containment policy actions based upon 50 States Surveys on state Medicaid spending growth and cost containment policy actions by the Kaiser Family Foundation in 2003. A cross-sectional study was performed to evaluate the impact of policy actions, by comparing Medicaid benefi ciaries to non-Medicaid-pharmacy-costcontainment-action-eligible residents. The outcome measures included: patients do not receive needed medical care, patients cannot afford needed prescriptions, patients postpone needed medical care, and patients worry about the medical care cost. The outcomes were analyzed using logit model, with prior authorization, generic drugs required, copayment method, step therapy of fail-fi rst requirement, limit on number of prescriptions and number of refi lls per month, preferred drug list, over the counter coverage, and prescription drug payment practices (payment and purchasing policies) as predictors. Additionally, non-pharmacy cost-containment policy actions, patients' demographics and states' socio-environmental variables were controlled. RESULTS: On average, each state has implemented 6.5% pharmacy cost containment policy actions in 2003. Only the worrying about costs was statistically signifi cantly associated with individual pharmacy cost-containment policy action; however, such signifi cance disappeared after other concurrent pharmacy cost-containment policy actions were controlled for. When the total number of pharmacy cost-containment policy actions was entered in the regression instead of individual policy action, each incremental policy action was associated with 14% increase in odds ratio for unmet medical needs (p 0.003), and 5% increase in odds ratio for postponing medical needs (p 0.02). CONCLUSIONS: There was variable impact of pharmacy cost-containment policy actions when assessed concurrently, and collectively.
PHP14 HAVE YOUR CAKE OR EAT IT: DO DECISIONS BASED ON COST-EFFECTIVENESS UNDERMINE INCENTIVES FOR RESEARCH AND DEVELOPMENT?
Walker SM 1 , Claxton K 2 1 University of York, York, North Yorkshire, UK, 2 University of York, York, UK OBJECTIVES: Although cost-effectiveness analysis allows effi cient decisions about the use of existing technologies (static effi ciency) it has been argued that it will disincentivise the development of innovative technologies (dynamic effi ciency). These concerns have also been raised about the report by the UK Offi ce of Fair Trading which recommended that the price of pharmaceuticals should be based on their cost-effectiveness. We aim to establish whether decisions based on cost-effectiveness necessarily undermine incentives for the development of pharmaceuticals. METHODS: The arguments put forward as to why cost-effectiveness decisions might undermine incentives for innovation are examined and are used to consider the implications of the type of value-based pricing which has been proposed in the UK. RESULTS: The argument depends on whether the purpose of health care is to improve population health or to maximise welfare (consumer and producer surplus). If it is the former, then achieving static and dynamic effi ciency requires a clear and predictable signal of value (costeffectiveness). The private sector can then choose to invest in developments which it believes will be cost-effective and provide a satisfactory return on investment. Manufacturers should be allowed to appropriate some share of the surplus (monopoly rent) to incentivise investment in R&D. However, they should not take it all. The public sector subsidises research and development in many ways. Therefore, even if society was unconcerned about who benefi ts from innovation it would not be effi cient to allow full appropriation. In other markets where innovation is protected, society simply offers monopoly rent during patent protection but does not allow full appropriation by, for example, facilitating perfect price discrimination. CONCLUSIONS: The argument that decisions about the use and price of a technology based on costeffectiveness will undermine the incentives for R&D is misplaced if the objective is to improve population health given a fi xed budget constraint.
